By Elliot Gulliver-Needham Astrazeneca’s lung cancer drug Imfinzi has been approved for treatment in the US to be used both before and after surgery, just days after the company’s market value hit £200bn for the first time. Imfinzi, which is meant to treat early-stage non-small cell lung cancer alongside chemotherapy, is administered before and after surgery. The approval by the US Food and Drug Administration (FDA) was based on positive results from trials in October 2023, which Astrazeneca said found a 32 per cent reduction in the risk of recurrence, progression or death compared to chemo al…